Cytokinetics prices upsized follow-on offering of 9,859,155 shares at $71 each
Cytokinetics, Incorporated
Cytokinetics, Incorporated CYTK | 0.00 |
- Cytokinetics priced an upsized underwritten public offering of 9,859,155 common shares at USD 71 per share.
- Gross proceeds expected at about USD 700 million, before underwriting discounts, commissions, and offering expenses.
- Closing expected May 8, 2026, subject to customary conditions.
- Underwriters received a 30-day option to buy up to 1,478,873 additional shares at offering price, less underwriting discounts and commissions.
- Morgan Stanley, Goldman Sachs, J.P. Morgan, Jefferies serving as joint book-runners.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605062300PRIMZONEFULLFEED9715188) on May 07, 2026, and is solely responsible for the information contained therein.